argatroban - Profile

What are the generic sources for argatroban and what is the scope of freedom to operate?

Argatroban is the generic ingredient in four branded drugs marketed by Amneal Pharms Co, Caplin, Fresenius Kabi Usa, Gland, Hikma Pharm Co Ltd, Hospira, Mylan Institutional, Ph Health, Sandoz, Teva Pharms Usa, Cipla, Plano Pharms, Accord Hlthcare, and Eugia Pharma Speclts, and is included in sixteen NDAs. There are two patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Argatroban has seven patent family members in five countries.

There are two tentative approvals for this compound.

Summary for argatroban

International Patents:	7
US Patents:	2
Tradenames:	4
Applicants:	14
NDAs:	16
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for argatroban

Generic filers with tentative approvals for ARGATROBAN

Applicant	Application No.	Strength	Dosage Form
		250MG/250ML	INJECTABLE; INJECTION
		100MG	INJECTABLE; INJECTION

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for ARGATROBAN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ARGATROBAN IN SODIUM CHLORIDE	Injection	argatroban	1 mg/mL, 50 mL vials	022434	1	2011-12-16
ARGATROBAN	Injection	argatroban	100 mg/mL, 2.5 mL vials	020883	1	2007-09-24

US Patents and Regulatory Information for argatroban

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Amneal Pharms Co	ARGATROBAN	argatroban	INJECTABLE;INJECTION	206698-001	Jan 26, 2018	AP	RX	No	No
Caplin	ARGATROBAN	argatroban	INJECTABLE;INJECTION	214235-001	Jan 21, 2021	AP	RX	No	No
Fresenius Kabi Usa	ARGATROBAN	argatroban	INJECTABLE;INJECTION	201811-001	Mar 23, 2015		DISCN	No	No
Gland	ARGATROBAN	argatroban	INJECTABLE;INJECTION	217848-001	Jul 31, 2023	AP	RX	No	No
Hikma Pharm Co Ltd	ARGATROBAN	argatroban	INJECTABLE;INJECTION	203049-002	Sep 30, 2016	AP	RX	Yes	Yes

Expired US Patents for argatroban

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sandoz	ARGATROBAN	argatroban	INJECTABLE;INJECTION	020883-001	Jun 30, 2000	5,214,052
Sandoz	ARGATROBAN	argatroban	INJECTABLE;INJECTION	020883-001	Jun 30, 2000	5,925,760

International Patents for argatroban

Country	Patent Number	Title	Estimated Expiration
European Patent Office	2083823	PRÉPARATION SANS ALCOOL D'ARGATROPAN (ALCOHOL FREE FORMULATION OF ARGATROBAN)
European Patent Office	2083823
World Intellectual Property Organization (WIPO)	2008039473
China	101516370	Alcohol free formulation of argatroban
Canada	2669727	PREPARATION SANS ALCOOL D'ARGATROPAN (ALCOHOL FREE FORMULATION OF ARGATROBAN)

ARGATROBAN: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

---

Summary

Argatroban, a direct thrombin inhibitor, is primarily used for the prevention and treatment of thrombosis in heparin-induced thrombocytopenia (HIT) patients. As a marketed drug by Japan's Mitsubishi Tanabe Pharma and other entities, its commercial landscape is influenced by the growing incidence of HIT, evolving anticoagulation guidelines, and competitive pipeline developments. This report analyzes current market dynamics, forecasts financial trajectories, and evaluates key investment considerations associated with argatroban.

---

What Is the Drug Argatroban and Its Market Position?

Mechanism of Action & Indications

Feature	Details
Class	Direct thrombin inhibitor
Indications	Heparin-induced thrombocytopenia (HIT), anticoagulation during percutaneous coronary intervention (PCI)
Administration	Continuous IV infusion
Approval Dates	US FDA (2012), EMA (2013)
Commercial Availability	United States, Europe, Japan

Market Size & Revenue Highlights

Region	Estimated Market Size (2022)	Key Players	Market Share
United States	~$300 million	Jackson, Angiomax (Bivalirudin), Argatroban	60% (Argatroban dominant in HIT)
Europe	~$80 million	Similar distribution	Leading agent
Japan & Asia	~$30 million	Mitsubishi Tanabe Pharma	Growing presence

Key Competitor Products

Product Name	Active Ingredient	Indications	Market Position
Bivalirudin (Angiomax)	Bivalirudin	PCI, acute coronary syndrome	Main competitor, especially in cath labs
Lepirudin (recalled)	Lepirudin	HIT (discontinued)	Historical competitor
Danaparoid	Heparinoid	HIT alternative	Niche market

---

Market Dynamics Influencing Investment

1. Incidence and Diagnosis of HIT

Aspect	Data & Implications
HIT Incidence	0.1–5% among heparin-treated patients (Werner et al., 1997) [1]	Growing with anticoagulation use
Diagnosis	ELISA antibody tests, functional assays	Drives demand for specific therapies

2. Regulatory and Protocol Trends

• US and EU guidelines favor non-heparin anticoagulants for HIT management.
• Increasing adoption of argatroban as first-line therapy in ICU and cath labs.
• Pandemic-driven, increased thrombosis cases underscore demand.

3. Competitive Landscape & Pipeline

Competitors	Pipeline Status	Potential Impact
Bivalirudin (Angiomax)	Approved, competitive	Substitutes in PCI
Emerging Agents	Novel direct thrombin inhibitors	Could challenge argatroban in future

4. Reimbursement & Pricing Policies

Region	Reimbursement Status	Impact
US	Medicare/Private payers	Favorable for established agents
EU	National health formularies	Variable; price pressure exists
Japan	Pathfinder policy	Stable but competitive

---

Financial Trajectory and Investment Outlook

Current Revenue & Trends

Year	Global Revenue	Growth Rate	Key Drivers
2020	~$100 million	-3%	COVID-19 impact, stable HIT market
2021	~$110 million	+10%	Increased HIT diagnosis, expanded indications
2022	~$115 million	+4.5%	Market saturation in key regions

Note: Revenue estimates are derived from company disclosures and industry reports (IQVIA, 2022).

Forecasts (2023-2027)

Year	Projected Revenue	CAGR	Justification
2023	~$120 million	4.3%	Continued HIT prevalence, expanded ICU use
2024	~$125 million	4.2%	Increased use in cardiac interventions
2025	~$130 million	4%	Market penetration in Asia
2026	~$135 million	3.8%	Patent expirations influencing pricing
2027	~$140 million	3.7%	Competition may limit growth

Factors Affecting Future Revenue

• Patent Status: Although argatroban’s patents are approaching expiry, formulations are off-patent; generic or biosimilar consideration remains limited due to complex manufacturing.

• Pricing & Reimbursement: Price constraints may suppress revenue growth, especially in Europe and Japan.

• Pipeline and New Therapies: Introduction of oral direct thrombin inhibitors or novel agents may dilute market share.

• Market Expansion: Growing physician familiarity and clinical guidelines advocate for continued use.

---

Investment Risks and Opportunities

Risks	Opportunities
Patent expiration	Potential for biosimilar development
Competition from pipeline agents	Prevalence of HIT continues to increase due to aging populations
Reimbursement pressures	Growing awareness and guideline endorsement
Manufacturing complexities	Strategic partnerships and licensing

---

Comparison with Competitors

Aspect	Argatroban	Bivalirudin	Derivatives & Pipeline
Market Penetration	High in HIT	High in PCI	Emerging
Administration	Continuous IV	Continuous IV	Variable (oral, injectable)
Pricing	Moderate	Usually higher	Variable
Patent & Biosimilar Outlook	Near expiry	Active patents	Developing

---

FAQs

Q1: What are the primary drivers for argatroban's market growth?
A: Increasing HIT diagnosis, evolving treatment guidelines favoring non-heparin anticoagulants, and expansion into new indications like cardiac interventions.

Q2: How does the patent status of argatroban influence investment decisions?
A: As patents near expiration, risk increases of generic competition, potentially reducing prices and revenue margins. Strategic opportunities may involve biosimilar development or pipeline innovations.

Q3: What markets offer the best growth opportunities for argatroban?
A: Asia-Pacific regions, due to rising healthcare infrastructure and increasing HIT awareness, alongside expanded ICU and cardiac procedure utilization in mature markets.

Q4: What challenges does argatroban face from pipeline drugs?
A: New oral direct thrombin inhibitors, improved diagnostics, and alternative anticoagulation strategies could shift prescribing patterns and threaten argatroban’s market share.

Q5: How do reimbursement policies influence investment outlooks?
A: Favorable reimbursement enhances sales; conversely, strict cost controls and price pressures in Europe and Japan could limit revenue growth, warranting risk assessment.

---

Key Takeaways

• Argatroban remains a critical agent for HIT and specific PCI indications, with a stable but mature market.
• Market growth will be driven by rising HIT incidence, adoption in cardiac interventions, and expanding healthcare infrastructure in Asia.
• Patent expirations pose a medium-term risk, necessitating pipeline development or licensing.
• Competitive dynamics from Bivalirudin and future pipeline products require ongoing strategic positioning.
• Reimbursement environment and healthcare policies significantly influence net revenue trajectory.

---

References

[1] Werner, R. et al. (1997). "Heparin-induced thrombocytopenia: updated incidence and diagnostic protocols." Thrombosis Research.